Journal of Hepatology

Article	Citations
A step forward to predict the risk of post-hepatectomy portal hypertension	2528
Further on ammonia concentration, -clearance, -removal, and -production	1494
Editorial Board	1164
Let’s unite Hepatology! Become an EASL member today and discover your benefits	1079
Reply to: “We need to talk about #livertwitter”	1035
Editorial Board	928
Reply to: “Reassessing the causal relationship between liver diseases and cardiovascular outcomes” and “From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank”	793
Get ready for the EASL Studio season 6!	316
Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody	293
Viral Hepatitis Elimination 2022 – Don’t miss this special conference in Brussels & register with early fees by 4 January!	291
Apply now for the EASL School 2022	281
From the Editor’s Desk...	268
A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease	266
From the Editor’s Desk...	262
Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms	252
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”	252
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April	243
Visit EASL Campus & discover 4,100 + resources on hepatology & liver-related research	242
Defining the prognosis of critically ill patients with alcohol-related liver disease	233
Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals	232
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis	225
Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease	223
Why weight loss is only half the battle: The epigenetic memory of adipose tissue	218
GEMA-Na: A crucial step in solving the MELD-creatinine dilemma	214
Peripheral fat mobilization and mitochondrial fat metabolism: Fueling the energy demands of liver regeneration	206

Reply to: “Rethinking methodology and data integrity in Mendelian randomization: Insights from air pollution and MASLD research”	202
Beyond Metabolic Benefits: The Underexplored Immunomodulatory Effects of GLP-1/Glucagon Agonists	197
Reply to: “Communicating the complexity of the transplant benefit score”	191
AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B	189
Reply to: “TIPS and liver transplantation should always be discussed together”	183
Join the EASL Community & enjoy reduced fees to all EASL events	183
Transient elastography in chronic liver disease: Beware of the cut-offs!	182
Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential	181
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH	180
Loss or gain of function: The functional complexity of the PNPLA3 I148M variant	178
Long-term use of tenofovir disoproxil fumarate and increased fracture risk in elderly patients with chronic hepatitis B: An E-value sensitivity analysis	175
Become an EASL Member & join the global liver community, or renew your membership	166
A pilot study to improve the uptake of hepatocellular carcinoma surveillance	164
Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease	164
Prevalence and incidence of delta hepatitis in HIV-HBV coinfected patients in the Dat’AIDS cohort	163
Estimating the economic value allocation of the social surplus generated by the utilization of second-generation direct-acting antivirals for hepatitis C in the United States, 2015–2019	161
SIRIUS project: sensing probe exploring liver fibrosis in Slovakia	160
Global burden of common cancers attributable to metabolic risks from 1990 to 2019	157
Opt-out testing for hepatitis B and C infections in adults attending the emergency department of a London Hospital	156
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers	153
The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: descriptive results from a cross-sectional study across Italy, Germany, Spain and	153
Late presentation of chronic hepatitis C for care in Georgia: data from the national hepatitis C elimination program, 2016–2021	149
One step closer to the goal: mobile InfoHep centre offering detection, protection, prevention and treatment/linkage- to care services in Croatian penalty institutions	148
Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona	147
Automation of hepatitis C screening through electronic health record algorithm	146
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021	145
Glycemic control as a modifiable and independent risk factor for the development of liver, biliary tract and pancreatic cancer: a territory-wide study of 273,421 patients with diabetes mellitus	142
FIB-4 outperforms other serum non-invasive fibrosis tests in metabolic associated fatty liver disease	142
Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver dise	139
Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the French prospective chief cohort	138
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm	138
Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C	138
Incidence of hepatitis D virus super-infection in HBsAg positive patients (The Inci-D cohort study)	137
Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib	136
Bisphosphonate-loaded nanogels attentuate liver fibrosis by repolarization of M2-type macrophages	135
Performance of the Steatosis-Associated Fibrosis Estimator (SAFE) to predict F2 fibrosis and higher in a cohort of South Korean patients with non-alcoholic fatty liver disease (NAFLD)	134
Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tol	134
Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery	131
Estimating the residual risk of hepatitis B mother-to-child transmission in The Gambia, 30 years after HBV vaccine implementation	130
Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002–2022)	130
Contrasting immune fingerprints of chronic hepatitis B Virus infection in adults from South Africa and the United Kingdom	129
Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment	127
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study	125
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis	125
Identification and external validation of the optimal ALT thresholds for ruling in significant histologic disease in chronic hepatitis B	123
Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB	122
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study	121
Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib	120
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis	120
Risk stratification for early recurrence after resection in patients with intermediate stage hepatocellular carcinoma	119

Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction	118
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling	117
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B	115
The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model	115
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece	115
Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions	114
Long-term outcome following liver transplantation for patients with acute on chronic liver failure grade 3 (ACLF-3): a retrospective matched-controlled study	114
Quantitative digital pathology of 3D human NASH models establish continuous scores to evaluate the antifibrotic effects of Selonsertib, Firsocostat and Resmetiron	113
Addressing the heterogeneity of fibrosis in liver biopsy specimens with qFibrosis – a new paradigm for an old problem	113
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis	112
Exploring gender-related differences in liver fibrosis and regeneration through a new experimental carbon tetrachloride protocol in mice	112
Sequential systemic treatment in patients with hepatocellular carcinoma: real-world data in the era of immune checkpoint inhibition	110
Epidemiological landscape and clinical spectrum of chronic hepatitis B in East Africa	108
Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis	108
Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model	108
Multispectral imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis reveals enrichment of pathogenic macrophage phenotypes associated with disease progression	108
Clinical impact of relative dose intensity over the first four weeks in cabozantinib therapy for unresectable hepatocellular carcinoma	107
Diabetes, but not prediabetes, is associated with significant liver fibrosis	106
Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease	105
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis	105
Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: results from the HCV-TARGET study	102
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease	101
Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5000 patients (in collaboration with NAIL-NIT consortium)	101
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients	100
LncRNA XR_592974.2 and circRNA _2599 regulated hypoxic stress response in hepatic stellate cells by targeting the miRNA-145/JMY/ P53 pathway	100
Eliminating viral hepatitis one island at a time-the Hainan experience	100
The comparisons of clinical relapse timing and severity after cessation of prophylactic nucleos (t)ide analogue between chronic hepatitis B patients with lymphoma receiving chemotherapy with and witho	99
A risk prediction model for hepatocellular carcinoma for non-alcoholic fatty liver disease without cirrhosis	99
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)	98
A history of bariatric surgery is independently associated with a younger age at onset of severe alcoholic hepatitis	97
Association between consumption of ultra-processed foods and non-alcoholic fatty liver disease in the Framingham heart study	97
MELD-sarcopenia and clinically significant portal hypertension as independent risk factors in the evolution of liver cirrhosis	97
A novel nomogram for predicting HBeAg clearance in HBeAg-positive chronic hepatitis B patients after nucleos (t)ide analogues treatment	97
Suppression of the pituitary-adrenal axis in stable outpatients with advanced chronic liver disease increases with disease severity and may be linked to systemic inflammation and bile acids	97
Use of the enhanced liver fibrosis test to risk stratify patients in the intelligent liver function test pathway: ruling out cirrhosis and advanced fibrosis	97
A novel autophagy inducer attenuated non-alcoholic steatohepatitis by regulating the adneylate cyclase 6 in hepatocytes	96
Infections are common in patients with early alcohol-related liver disease and increases the risk of death	96
Antibody response to gut microbiome bacteria in human alcoholic liver disease	96
Bacterial translocation has an early onset in cirrhosis and induces a selective inflammatory response	96
Targeting cyclin M4 as a new therapeutical approach to treat alcoholic liver disease	96
Rilpivirine as an anti-inflammatory agent in non-alcoholic fatty liver disease: evidence from human hepatocytes, hepatic stellate cells and blood cells	95
Abstinence is associated with better outcome in patients with hepatocellular carcinoma	95
Hepatic transcriptional signature of alcohol on genes involved in canonical retinoid metabolism	95
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice	94
Ultrasound predictors of hemodynamic TIPS dysfunction: friends or foes?	94
Baveno VII algorithm can avoid endoscopic surveillance in patients with cirrhosis	92
Validation of a discrete event simulation model evaluating the cost-effectiveness of long-term albumin administration in real-world UK patients with recurrent ascites	92
IFI16 expression and its genotype variant are associated with NAFLD progression	92
Characterizing the histologic implications of resmetirom-induced liver volume reduction using artificial intelligence-powered digital pathology	91
Opposite correlations between hepatic β-oxidation activity and triglyceride levels in male and female rats after a high-fat diet supplemented with liquid fructose	91
Evaluation of genetic risk score of a dysmetabolic and obese population of southern Italy	91
Administration of Lactulose, Rifaximin, or combination therapy for hepatic encephalopathy is associated with a reduction in gastrointestinal cancers	90
Selective modulation of mitochondrial complex I ameliorates steatosis and hepatic inflammation in MCD-diet fed rats	90
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction	89
A guinea pig model of pediatric non-alcoholic steatohepatitis	89
Preclinical efficacy and clinical translatability of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH	89
Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice	89
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease	87
Non-invasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2-F3 NASH patients: secondary analysis of Ph2b HARMONY study	87
Identification of new dominant neoantigens in hepatocellular carcinoma based on a single plasmid system with co-expressing patient’s HLA and antigen	86
Molecular insights into the tumour suppressor role of Protein Phosphatase 2A B56 delta complex in human liver, and its clinically relevant inhibition by cancerous inhibitor of PP2A	86
Carvedilol is associated with superior hemodynamic response and rebleeding rates in comparison to propranolol in secondary prophylaxis of variceal bleeding	86
A novel immunophenotyping of hepatocellular carcinoma based on amplified and mutated neoantigens for mRNA vaccine development	86
The pan-PPAR agonist lanifibranor decreases portal pressure in models of both hepatic and prehepatic portal hypertension	85
High-risk Thrombophilia predict early thrombosis recurrence in acute non-cirrhotic portal vein thrombosis related to local factors: LOCAPORT	85
Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)	85
SAFE score yielded a better performance than FIB-4 and NFS in predicting significant fibrosis among Asian NAFLD patients	85
Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions	84
Monoacylglycerol lipase inhibition specifically in macrophages compromises liver regeneration by inducing interferon type 1 that negatively impacts on hepatocyte proliferation	84
Biological differences between clinically different muscle wasting phenotypes in patients with decompensated ESLD undergoing assessment for liver transplantation: a UK prospective cohort UK study	84
The uptake of extracellular lipids promotes cholangiocarcinoma progression	84
A systematic review and meta-analysis of the prevalence and cross-sectional severity of South Asian patients with non-alcoholic fatty liver disease	84
Dynamic organotypic culture of primary liver cancer as a personalised immunocompetent drug screening platform for immuno-oncology	84
Ribosomal protein encoding genes: potential drivers of primary sclerosing cholangitis associated cholangiocarcinoma	83
Neurological dysfunction is improved after faecal microbiota transplantation in rats with bile duct ligated-induced chronic liver disease	83
miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC	83
Nutritional therapy improves minimal hepatic encephalopathy in cirrhosis by improvement in sarcopenia, proinflammatory cytokines and myostatin: a double blind randomized controlled trial	82
Single cell RNAsequencing derived signature of hepatocyte de-differentiation predicts development of hepatocellular carcinoma in patients with liver cirrhosis	81
Real-world treatment of decompensated liver cirrhosis in Italy: a propensity score-matched analysis of long-term versus acute albumin therapy	80
Critical investigation on the usability of hepatoma cell lines HepG2 und Huh7 as models for the metabolic representation of resectable hepatocellular carcinoma	80

Radiomic model based on contrast-enhanced CT imaging to predict early recurrence for patients with hepatocellular carcinoma after radical resection	79
Effects of nutritional therapy on Sarcopenia in patient with liver cirrhosis-a randomised controlled trial	79
Targeting Apolipoprotein J restores autophagy and improves metabolic-associated fatty liver disease and diabetic nephropathy	78
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis	77
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD	77
Development of a target engagement biomarker for HSD17B13: preclinical pharmacodynamic studies of small molecule inhibition of HSD17B13 by INI-822	77
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study	76
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)	76
NFATc1 drives progressive liver inflammation and fibrosis by regulating pro-apoptotic stress responses	75
Peroxisome proliferator-activated receptor alpha and estrogen related receptor alpha ligand combinations ameliorate non-alcoholic fatty liver disease	75
Development and external validation of a model to predict multi-drug resistant bacterial infections in patients with cirrhosis	75
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis	75
Human antigen R (HuR) is a master regulator of hepatic glucose metabolism	75
Primary cilia in biliary regeneration-a potential approach to improve outcomes in liver transplantation	74
Magnesium modulation by CNNM4 silencing in DIAMOND mice via GalNAc-siRNA therapy: a new and effective therapeutic approach against MAFLD	74
Goals of care and end-of-life for patients with advanced liver disease followed by a specialized palliative care clinic	74
The PNPLA3 I148M variant aggravates inflammation through dysfunctional LXR and PPAR gamma signalling in macrophages	73
A novel HIF2A mutation causes dyslipidemia and promotes hepatic lipid accumulation	73
Statins regulate PNPLA3 through a mechanism that requires SREBF2 in human liver cells	72
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease	72
The prevalence and prognostic impact of myosteatosis with and without sarcopenia and its association with age and severity of liver cirrhosis	72
A heterozygous N559Y mutation in Semaphorin 7A promotes non-alcoholic fatty liver disease progression through induction of hepatic ROS production and inflammation	72
Liver nutrition clinic improves nutritional outcomes in patients with advanced cirrhosis	71
24-Hour urinary creatinine excretion (UCE) a marker of muscle mass is associated with mortality in critically ill patients with cirrhosis	71
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks	71
Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making	71
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis	71
Experiences from a palliative care clinic specialized in liver diseases-utilisation, clinical characteristics of patients and outcomes	71
Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers	70
A preferable signature of gut microbiota and bile acids predicted better outcomes of unresectable hepatocellular carcinoma to immune checkpoint inhibitors	69
Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD)	69
The prognostic role of lysophosphatidylcholines and their immunomodulatory potential in acute liver failure	68
Increasing gut microbiota produced secondary bile acids to protect against non-alcoholic steatohepatitis	68
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices	68
Low hemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation	67
Modeling ischemic cholangiopathy in human cholangiocyte organoid for screening of novel cholangio-protective agents	67
A novel imaging approach to investigate hepatitis E virus entry	67
The inhibition of the epigenetic efectors DNMT1 and G9a as a potential therapeutic strategy against the non-alcoholic fatty liver development	67
Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study	66
Add-on benefits of AFP-L3, PIVKA-II and GALAD score to ultrasound plus AFP for surveillance of hepatocellular carcinoma	65
Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure	65
Sarcopenia assessed via computed tomography is associated with short-term outcomes and improves prognostic scores’ performance in critically ill patients with acute on chronic liver failure	65
Beta-blockers can reduce mortality in patients with acute-on-chronic liver failure-a multi-center study	65
Poster Presentation - Table of Contents	64
The efficacy of direct-acting antivirals for chronic hepatitis C in patients with the active oncological disease	64
The regulatory protein and gene expression profile of skeletal muscle in chronic liver disease patients	64
Combination of CCL4-induced decompensated cirrhosis with acute polymicrobial peritonitis as an optimized experimental model mimicking extrahepatic organ failures defined in ACLF	64
Exacerbated response to patterned injury in the cirrhotic liver: potential susceptibility to ischemia	64
Transversal psoas muscle thickness measurement is associated with response and survival in patients with hepatocellular carcinoma undergoing immunotherapy	64
Altered metabolic program initiates immune activation leading to hepatitis B surface antigen seroconversion in mild and severe hepatitis B reactivation patients	63
Ascites reduction and anti-inflammatory effects after albumin infusion for the management of cirrhosis: evidence from an animal model	63
Demonstration of gut-barrier dysfunction and endotoxemia in patients with cirrhosis presenting with acute variceal bleeding: a proof of concept	63
Effect of liver stiffness on hepatocellular carcinoma phenotype in a biometric 3D model	63
Survival of patients with advanced hepatocellular carcinoma treated with sorafenib in France during 2009–2018: analysis of the French hospital and claim database	62
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma	62
Transarterial radioembolisation in non resectable hepatocellular carcinoma in curative strategies: a single centre experience	62
Disclosures: commercial relationships	62
Identification of resistance-associated variants after sofosbuvir treatment in chronic hepatitis E patients	61
Incidence of hepatocellular carcinoma reduced in chronic hepatitis B patients treated with entercavir plus Biejia-Ruangan: extended follow-up of a multicenter, randomised, double-blinded, placebo-cont	61
HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg (-) predicts long-term HBV control	60
Epigenetic modulation by DNA methyltransferase inhibition may enhance the effect of immune checkpoint inhibitors to restore HBV-specific T cell responses	59
Prophylactic vaccine against hepatitis D virus (HDV) superinfection	59
In vitro and in vivo preclinical efficacy of PD-L1-targeted liposomal doxorubicin as a combined therapy for the treatment of hepatocellular carcinoma	59
Impact of endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy	59
Association of gut microbiome with prospective risk of hepatocellular carcinoma in chronic hepatitis B patients: a prospective nested case-control study	58
Hepatitis B pre-genomic RNA level has a prospective supporting role for predicting the outcomes of the hepatitis B virus inactive carrier phase	58
Impact of obesity on outcome of hepatocellular carcinoma in an Asian cohort: when should we consider obesity treatment?	58
Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study	58
Management of severe, steroid-resistant and steroid-refractory hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy	58
Combination of systemic immune-inflammation index and albumin-bilirubin score predict prognosis of sequential therapy with sorafenib and regorafenib in unresectable hepatocellular carcinoma	58
Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)	58
Drug screening for hepatocellular carcinoma: automating and miniaturizing organoid assays for drug screening	58
Serum villin-1 level-a tell-tale sign of gut barrier failure in patients with cirrhosis and acute decompensation	58
Clinical course of biopsy-controlled alcohol-related liver disease	58
Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease	58
Remodeling of myeloid cells during hepatocellular carcinoma driven by beta-catenin activation	57
Place of steroids and prognosis factors for grade = 3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study	57
Exogenous fibroblast growth factor 7 improved hepatocyte regeneration and ameliorated CCl4-induced acute liver injury in vivo	57
HDV full genome sequencing and sensitive HBV genotyping from a large cohort of HBV/HDV co-infected patients	57
Lactobacillus protects against leaky gut, future decompensation, and hepatic encephalopathy in patients with cirrhosis	57
Online education significantly improved gastroenterologists’ knowledge of the diagnostic and monitoring techniques used in liver fibrosis	56
A PKA-associated liver-tissue rheostat curbs T cell receptor signalling and effector function of virus-specific CD8 T cells in chronic viral hepatitis	56
Impact of oral semaglutide on liver pathology and glucose metabolism in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus	56
Semaglutide improves non-alcoholic steatohepatitis: a 10-year retrospective study	55
Comparison of efficacy between liraglutide and phentermine/topiramate in obese patients with non-alcoholic fatty liver disease	55
Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1	55
The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients	55
The influence of probiotics on biologic and imagistic alterations in non-alcoholic steato-hepatitis	55
Safety and signal intensity of a novel liver-specific MRI contrast agent, Orviglance® (manganese chloride tetrahydrate), in adult subjects with mild, moderate, or severe hepatic impairment	54
Validation of cut-off values proposed by the society of radiologists in ultrasound liver elastography for diagnosis of compensated advanced chronic liver disease using 2D shear wave elastography	54
Dynamics of liver stiffness measurements provide incremental prognostic information in advanced chronic liver disease	54
Effectiveness of vaccine education on vaccine awareness and vaccine uptake in patients with cirrhosis of liver of a tertiary care center in South India	53
Head-to-head comparison of the prognostic performance of the hepatic venous pressure gradient and non-invasive tests in compensated advanced chronic liver disease	52
A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease	52
X-box binding protein 1 (XBP1) in hepatic stellate cells (HSC) mitigates liver fibrosis	52